NOVARTIND — Novartis India Cashflow Statement
0.000.00%
- IN₹16.60bn
- IN₹11.67bn
- IN₹3.79bn
- 59
- 22
- 50
- 36
Annual cashflow statement for Novartis India, fiscal year end - March 31st, INR millions except per share, conversion factor applied.
2019 March 31st | 2020 March 31st | 2021 March 31st | 2022 March 31st | 2023 March 31st | |
---|---|---|---|---|---|
Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
Source: | ARS | ARS | ARS | ARS | ARS |
Standards: | IAS | IAS | IAS | IAS | IAS |
Status: | Final | Final | Final | Final | Final |
Net Income/Starting Line | 858 | 286 | 400 | -38.2 | 1,154 |
Depreciation | |||||
Non-Cash Items | -758 | -249 | -171 | -153 | -550 |
Unusual Items | |||||
Other Non-Cash Items | |||||
Changes in Working Capital | -2,074 | -400 | -1,043 | 481 | -217 |
Change in Accounts Receivable | |||||
Change in Inventories | |||||
Change in Other Assets | |||||
Change in Accounts Payable | |||||
Change in Other Liabilities | |||||
Other Operating Cash Flow | |||||
Cash from Operating Activities | -1,943 | -231 | -692 | 387 | 448 |
Capital Expenditures | -141 | -10 | -0.9 | -5 | -3.1 |
Purchase of Fixed Assets | |||||
Other Investing Cash Flow Items | 2,883 | 569 | 953 | 875 | -1,529 |
Sale of Fixed Assets | |||||
Change in Net Investments | |||||
Other Investing Cash Flow | |||||
Cash from Investing Activities | 2,742 | 559 | 952 | 870 | -1,533 |
Financing Cash Flow Items | -50.8 | -115 | -65.4 | -0.4 | -0.5 |
Other Financing Cash Flow | |||||
Total Cash Dividends Paid | |||||
Net Issuance / Retirement of Stock | |||||
Net Issuance / Retirement of Debt | |||||
Cash from Financing Activities | -298 | -414 | -368 | -356 | -305 |
Beginning Cash Balance | |||||
Ending Cash Balance | |||||
Net Change in Cash | 501 | -86.4 | -109 | 901 | -1,389 |